Rodman & Renshaw Maintains Market Perform on Catalyst Pharmaceutical Partners

Rodman & Renshaw maintained its Market Perform rating on Catalyst Pharmaceutical Partners CPRX. In a research report published today, Rodman & Renshaw stressed it remains cautiously optimistic about the performance of some of Catalyst's new drugs. In the report, Rodman & Renshaw states, "We are cautiously optimistic about the new Phase 2b study of CPP-109, and believe that if approved, CPP-109 may have a substantial commercial value in the addiction market. Additionally, the preclinical data suggests that CPP-115 (wider therapeutic window, longer patent life, new indications) may be an excellent follow-on drug to CPP-109. We look forward to future updates on the development of the company's pipeline." On Thursday, Catalyst added 1.14% to its value to close the day at $1.78. Its shares lost all of yesterday's gains in today's pre-market trading, however, sliding 4.49% to $1.70.